Table 1.
Baseline characteristics and incidence rates of outcomes in patients with and without psoriasis
| BASELINE CHARACTERISTICS | |||||||
| Any Psoriasis | Mild Psoriasis | Moderate-to-severe Psoriasis | |||||
| Unexposed | Overall PsO | Unexposed | Mild PsO | Unexposed | Moderate-to-severe PsO | ||
| N | 1,019,140 | 205,815 | 955,721 | 193,013 | 63,415 | 12,806 | |
| Age, mean (SD) | 50.66 (17.82) | 47.17 (17.55) | 50.62 (17.83) | 47.00 (17.67) | 51.36 (17.68) | 49.83 (15.30) | |
| Female sex, N (%) | 570,359 (55.96) | 106,569 (51.78) | 534,679 (55.94) | 99,975 (51.80) | 35,676 (56.26) | 6,598 (51.52) | |
| BMI, mean (SD)1 | 26.39 (5.47) | 26.76 (5.64) | 26.40 (5.47) | 26.66 (5.59) | 26.37 (5.38) | 28.11 (6.11) | |
| Drinking history, N (%)2 | |||||||
| None | 115,738 (11.36) | 21,634 (10.51) | 108,415 (11.34) | 20,221 (10.48) | 7,321 (11.54) | 1,415 (11.05) | |
| Current | 651,393 (63.92) | 133,805 (65.01) | 611,581 (63.99) | 125,285 (64.91) | 39,811 (62.78) | 8,521 (66.54) | |
| Past | 43,615 (4.28) | 8,257 (4.01) | 41,052 (4.30) | 7,398 (3.83) | 2,562 (4.04) | 860 (6.72) | |
| Smoking history, N (%)3 | |||||||
| None | 488,477 (47.93) | 80,067 (38.90) | 458,226 (47.95) | 75,124 (38.92) | 30,249 (47.70) | 4,945 (38.61) | |
| Current | 219,759 (21.56) | 58,963 (28.65) | 206,406 (21.60) | 55,579 (28.80) | 13,351 (21.05) | 3,386 (26.44) | |
| Past | 209, 354 (20.54) | 45,790 (22.25) | 196,829 (20.59) | 42,073 (21.80) | 12,525 (19.75) | 3,717 (29.03) | |
| Townsend4, median quintile (IQR) | 3 (1,4) | 3 (2,4) | 3 (1,4) | 3 (2,4) | 3 (1,4) | 3 (1,4) | |
| Hypertension | 210,359 (20.64) | 35,801 (17.39) | 196,995 (20.61) | 32,939 (17.07) | 13,362 (21.07) | 2,864 (22.36) | |
| Diabetes | 67,635 (6.64) | 12,558 (6.10) | 63,499 (6.64) | 11,349 (5.88) | 4,136 (6.52) | 1,209 (9.44) | |
| Hyperlipidemia | 95,117 (9.33) | 16,734 (8.13) | 89,114 (9.32) | 15,346 (7.95) | 6,003 (9.47) | 1,388 (10.84) | |
| Cardiovascular disease (CVD)5 | 90,411 (8.87) | 15,530 (7.55) | 84,404 (8.83) | 14.459 (7.49) | 14,459 (7.49) | 6,007 (9.47) | |
| Psoriatic arthritis | Not applicable | 10,308 (5.01) | Not applicable | 5,504 (2.85) | Not applicable | 4,804 (37.51) | |
| NSAID use | 537,227 (52.71) | 93,476 (45.42) | 504,529 (52.79) | 84,373 (43.71) | 32,698 (51.56) | 9,106 (71.11) | |
| INCIDENCE RATES OF IgA NEPHROPATHY AND GLOMERULAR DISEASE IN PATIENTS WITH AND WITHOUT PSORIASIS | |||||||
| Any Psoriasis | Mild Psoriasis | Moderate-to-severe Psoriasis | |||||
| Unexposed | Overall PsO | Unexposed | Mild PsO | Unexposed | Moderate-to-severe PsO | ||
| IgAN | |||||||
| Median (IQR) duration of follow- up years |
5.57 (2.37,9.92) | 5.19 (2.15,9.60) | 5.53 (2.35,9.87) | 5.26 (2.17,9.71) | 6.30 (2.89,10.75) | 4.39 (1.92,7.85) | |
| Number (%) of new IgAN cases | 113 (0.01) | 29 (0.01) | 100 (0.01) | 24 (0.01) | 13 (0.02) | 5 (0.04) | |
| Incidence of IgAN per 100,000 person years (95% CI) |
1.71 (1.42–2.06) | 2.28 (1.58–3.28) | 1.63 (1.34–1.98) | 1.99 (1.34–2.97) | 2.92 (1.70–5.03) | 7.33(3.05–17.62) | |
| Glomerular disease | |||||||
| Median (IQR) duration of follow- up, years |
5.57 (2.37,9.92) | 5.19 (2.15,9.60) | 5.52 (2.35,9.86) | 5.26 (2.17,9.71) | 6.29 (2.89,10.75) | 4.39 (1.93,7.85) | |
| Number (%) of new glomerular disease cases |
467 (0.05) | 93 (0.05) | 427 (0.04) | 83 (0.04) | 40 (0.06) | 10 (0.08) | |
| Incidence of glomerular disease per 100,000 person years (95% CI) |
7.08 (6.47–7.75) |
7.31 (5.96–8.95) |
6.94 (6.31–7.63) | 6.89 (5.56–8.54) | 8.98 (6.59–12.25) | 14.67 (7.89–27.26) | |
p<0.001 for all
19.78% and 20.37% of BMI data were missing in patients without and with psoriasis, respectively
20.45% and 20.46% of drinking data were missing in patients without and with psoriasis, respectively
9.96% and 10.20% of data on smoking habits were missing in patients without and with psoriasis, respectively
Townsend score is a proxy of socioeconomic status based on employment status, car/home ownership, and household overcrowding. A higher Townsend index score correlates with greater socioeconomic deprivation (lower socioeconomic status). 4.12% and 4.87% of data on Townsend score were missing in patient without and with psoriasis, respectively.
Congestive heart failure, coronary artery disease, myocardial infarction, or peripheral artery disease